Amber Luong, MD, PhD, FACS - Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PRZ865. CME/MOC/CC/AAPA/IPCE credit will be available until April 20, 2027.Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.